SPOTLIGHT -
EP. 1: Introduction: Radioactive Iodine-Refractory DTC
EP. 2: Determining Treatment for RAI-Refractory Thyroid Cancer
EP. 3: Available Treatment Options for RAI-Refractory DTC
EP. 4: Sequencing Therapies in Differentiated Thyroid Cancer
EP. 5: Patient Selection for Systemic Therapy in DTC
EP. 6: Role of the Endocrinologist in RAI-Refractory Thyroid Cancer
EP. 7: Case Study: Treating Papillary Thyroid Cancer
EP. 8: Managing Sorafenib-Related AEs in Thyroid Cancer
EP. 9: Diagnosis and Initial Treatment of MTC
EP. 10: Utilizing TKIs in Advanced Medullary Thyroid Cancer
EP. 11: Treatment Selection in Advanced MTC
EP. 12: Importance of Multidisciplinary Thyroid Cancer Care
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
